Free market capitalism is, in theory, about a kind of economic Darwinism. The fittest will survive and thrive while the weakest face a certain, if unpleasant fate. Of course, it doesn't always work that way. As the adoption of TARP and the bailout of the U.S. auto companies during the financial crisis showed, the concept of “too big to fail” crosses ideological and party lines and is a fact of life in the modern world
This leaves the dire consequences of failure as anything but certain. The survival and success of the fittest, however, particularly during difficult times, can still give investors valuable indications as to what may constitute a good long term investment. When medical device company Hologic (HOLX )
Conventional wisdom maintains that these are indeed difficult times for the medical device industry, and that they will soon become a little less difficult. It is frequently said that the medical device tax that was a part of Obamacare has put a squeeze on the industry and that the Republican gains in the mid-term elections will result in its repeal. A case can easily be made that neither of these statements is actually relevant to the performance of individual companies, nor even true.
The tax applies across the industry so no individual company is at a particular disadvantage, and medical devices, like many healthcare products, have fairly inelastic demand. If your doctor believes you need one, then a 2.3 percent tax on the device is unlikely to sway that opinion. A Congressional Research Service report published at Modernhealthcare.com came to just that conclusion, that the tax would have a negligible effect on both the producers of medical devices and on overall healthcare costs.
The reality for medical device producers, then, is not as bad as some would suggest. What the advent of the tax has done, though, is to prompt companies to look for improvement efficiencies, which is never a bad exercise for a company in a business with inelastic demand.
That doesn’t mean that the new Republican majority in Congress won’t attempt to repeal the tax, however. It is one part of a law that they oppose that has some bi-partisan opposition. The tax is cast as a tax on jobs and as such an attempt to repeal has too much political appeal to be ignored.
Whether it will pass the President’s veto pen or not depends on whether there is some other way of funding the resultant shortfall in Obamacare funding. If not, the President would see it as a backdoor way to put pressure on his signature achievement and reject any repeal bill.
To Hologic, however, it seems that none of these political shenanigans really matter. They are doing what good companies do when faced with a less than ideal market; going about their business of growing and making money. Yesterday’s results showed a beat on both the top and bottom lines. The 5year chart for HOLX confirms the impression of a company that has continued to grow, even as its industry becoming a political football has caused some volatility in the stock.
There has been a positive reaction to yesterday’s earnings, with the stock indicating gains of around 2-2.5 percent at the opening this morning. That, and the past volatility of the stock, may make a delayed purchase strategy more profitable than an outright buy at these levels. If, as discussed above, any attempt to repeal the medical device tax is vetoed by a President with nothing to lose it is likely that HOLX, along with all medical device companies, would fall quite precipitously.
That said, it would be a shame to miss out on a company that has demonstrated the ability to grow through consistently as you wait for a correction that may not come. It could even be that Obama, concerned about a perception of intransigence would care more about his legacy than any budget implications and not veto a repeal of the tax. In that case all medical device stocks would get a boost. It makes far more sense to adopt a strategy of controlled averaging in a situation like this.
Buy half of your intended total position at market and then set two more orders, even if just in your head. One would be to buy at last month’s low around $23 and the other to buy at around $29 should the stock continue on upward. (Incidentally if you physically place these orders, don’t forget to include the instruction that one cancels the other).
This would leave you with a full position at either $25 or $27.50. Either way you would own stock in a company that has shown the ability to work through whatever Washington throws at it and still make money and continue to grow. That has to be a good thing.
Source: http://www.nasdaq.com/article/despite-washington-this-medical-device-company-keeps-growing-cm410931#ixzz3IKaa311w
No comments:
Post a Comment